EGLN2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL523000	0.70	19/20
SCHEMBL523001	0.70	19/20
SCHEMBL522777	0.68	19/20
SCHEMBL522778	0.68	19/20
SCHEMBL522929	0.59	19/20
SCHEMBL523386	0.55	19/20
SCHEMBL523387	0.55	19/20
SCHEMBL522689	0.55	19/20
SCHEMBL523667	0.54	19/20
SCHEMBL523668	0.54	19/20
SCHEMBL523263	0.62	18/20
SCHEMBL523441	0.58	18/20
SCHEMBL523442	0.58	18/20
SCHEMBL522859	0.53	18/20
SCHEMBL522860	0.53	18/20
SCHEMBL522573	0.80	17/20
SCHEMBL522552	0.67	17/20
SCHEMBL522721	0.67	17/20
SCHEMBL523170	0.67	17/20
SCHEMBL523592	0.64	17/20

Clinical trials — most relevant to EGLN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma	PHASE3	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
Study of the Effects of Iron on Lung Blood Pressure at High Altitude	PHASE2	WITHDRAWN
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)	PHASE2	UNKNOWN
Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients	PHASE1/PHASE2	RECRUITING
Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing	PHASE1	WITHDRAWN
Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment	PHASE1	COMPLETED
Repeat Dose Safety Study for Compound to Treat Anemia	PHASE1	COMPLETED
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases	PHASE1	COMPLETED
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer	EARLY_PHASE1	COMPLETED
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery	nan	COMPLETED
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Selecting Hypoxic Tumours for Treatment Modification	nan	RECRUITING
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock	nan	COMPLETED
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure	nan	UNKNOWN
Drivers of Hypoxia-induced Angiogenesis in Tumor Development	nan	UNKNOWN
Study of the Effects of Iron Levels on the Lungs at High Altitude	nan	COMPLETED
Genes-in-Action - Hepcidin Regulation of Iron Supplementation	nan	COMPLETED
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma	nan	RECRUITING
Hypoxia Inducible factor1-Alpha Genetic Polymorphism of Obstructive Sleep Apnea	nan	UNKNOWN
Role of HIF-1α in Skeletal Muscle Aging	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a EGLN2 binder may also engage these)

Protein	Name	Similarity
Q91YE2	—	1.000	Q91YE2 →
Q6AYU4	—	1.000	Q6AYU4 →
P59722	—	0.992	P59722 →
EGLN1	Egl nine homolog 1	0.991	landscape →
Q91YE3	—	0.989	Q91YE3 →
Q9UPV7	—	0.987	Q9UPV7 →
Q7XT42	—	0.986	Q7XT42 →
P89463	—	0.986	P89463 →
Q28969	—	0.985	Q28969 →
CABLES1	CDK5 and ABL1 enzyme substrate 1	0.985	landscape →
P54748	—	0.984	P54748 →
KCNH3	Voltage-gated inwardly rectifying potassium channel KCNH3	0.983	landscape →
O89084	—	0.983	O89084 →
Q49I57	—	0.983	Q49I57 →
Q8K3A9	—	0.983	Q8K3A9 →
P10290	—	0.983	P10290 →
Q5R4R7	—	0.983	Q5R4R7 →
O89047	—	0.983	O89047 →
Q9TUX8	—	0.983	Q9TUX8 →
Q566C8	—	0.983	Q566C8 →
Q8TBC3	—	0.983	Q8TBC3 →
P20024	—	0.982	P20024 →
O43900	—	0.982	O43900 →
A0A1W2PPD8	—	0.982	A0A1W2PPD8 →
A8JQX3	—	0.982	A8JQX3 →
A3KMV1	—	0.982	A3KMV1 →
Q80UE6	—	0.982	Q80UE6 →
Q5U5Q3	—	0.982	Q5U5Q3 →
Q0DCT8	—	0.982	Q0DCT8 →
Q3ULB5	—	0.982	Q3ULB5 →